ImmunoTech

Recent news mentioning ImmunoTech

• 2026-08-10 — AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer
• 2026-08-03 — AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point

Appears alongside

• AIM

Browse the full archive →